ZA200804180B - Bread improver comprising emulsifier and stabiliser - Google Patents
Bread improver comprising emulsifier and stabiliser Download PDFInfo
- Publication number
- ZA200804180B ZA200804180B ZA200804180A ZA200804180A ZA200804180B ZA 200804180 B ZA200804180 B ZA 200804180B ZA 200804180 A ZA200804180 A ZA 200804180A ZA 200804180 A ZA200804180 A ZA 200804180A ZA 200804180 B ZA200804180 B ZA 200804180B
- Authority
- ZA
- South Africa
- Prior art keywords
- agent
- gene
- disorder
- pro386
- disruption
- Prior art date
Links
- 239000003995 emulsifying agent Substances 0.000 title 1
- 235000010037 flour treatment agent Nutrition 0.000 title 1
- 239000003381 stabilizer Substances 0.000 title 1
- 230000003247 decreasing effect Effects 0.000 claims description 342
- 238000000034 method Methods 0.000 claims description 185
- 238000012360 testing method Methods 0.000 claims description 180
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 179
- 229920001184 polypeptide Polymers 0.000 claims description 154
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 154
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 154
- 241001465754 Metazoa Species 0.000 claims description 144
- 239000003795 chemical substances by application Substances 0.000 claims description 142
- 108090000623 proteins and genes Proteins 0.000 claims description 139
- 241000282414 Homo sapiens Species 0.000 claims description 131
- 230000009261 transgenic effect Effects 0.000 claims description 113
- 210000004027 cell Anatomy 0.000 claims description 97
- 239000005557 antagonist Substances 0.000 claims description 80
- 239000000556 agonist Substances 0.000 claims description 73
- 230000000694 effects Effects 0.000 claims description 65
- 239000003814 drug Substances 0.000 claims description 46
- 230000009547 development abnormality Effects 0.000 claims description 39
- 230000002829 reductive effect Effects 0.000 claims description 34
- 208000030159 metabolic disease Diseases 0.000 claims description 32
- 230000000771 oncological effect Effects 0.000 claims description 29
- 229940124597 therapeutic agent Drugs 0.000 claims description 28
- 230000035899 viability Effects 0.000 claims description 27
- 210000004369 blood Anatomy 0.000 claims description 25
- 239000008280 blood Substances 0.000 claims description 25
- 230000037396 body weight Effects 0.000 claims description 25
- 231100001129 embryonic lethality Toxicity 0.000 claims description 23
- 206010012601 diabetes mellitus Diseases 0.000 claims description 22
- 230000014509 gene expression Effects 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 230000035755 proliferation Effects 0.000 claims description 13
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 11
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 11
- 210000001626 skin fibroblast Anatomy 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 8
- 241001529936 Murinae Species 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000003278 mimic effect Effects 0.000 claims 1
- 230000001965 increasing effect Effects 0.000 description 276
- -1 survival factors Substances 0.000 description 139
- 210000002966 serum Anatomy 0.000 description 134
- 208000035475 disorder Diseases 0.000 description 106
- 101100446997 Prochlorococcus marinus (strain SARG / CCMP1375 / SS120) folD gene Proteins 0.000 description 101
- 101000730580 Homo sapiens Polycystic kidney disease protein 1-like 1 Proteins 0.000 description 99
- 102100032580 Polycystic kidney disease protein 1-like 1 Human genes 0.000 description 99
- 101100082821 Homo sapiens PECR gene Proteins 0.000 description 97
- 102100027506 Peroxisomal trans-2-enoyl-CoA reductase Human genes 0.000 description 97
- 230000004044 response Effects 0.000 description 90
- 101100485741 Prochlorococcus marinus (strain SARG / CCMP1375 / SS120) Pro_1271 gene Proteins 0.000 description 89
- 102100030323 Epigen Human genes 0.000 description 86
- 101000938352 Homo sapiens Epigen Proteins 0.000 description 86
- 210000000988 bone and bone Anatomy 0.000 description 81
- 208000019901 Anxiety disease Diseases 0.000 description 78
- 101000836954 Homo sapiens Sialic acid-binding Ig-like lectin 10 Proteins 0.000 description 78
- 102100027164 Sialic acid-binding Ig-like lectin 10 Human genes 0.000 description 78
- 208000012902 Nervous system disease Diseases 0.000 description 70
- 150000007523 nucleic acids Chemical class 0.000 description 68
- 210000003719 b-lymphocyte Anatomy 0.000 description 61
- 108091028043 Nucleic acid sequence Proteins 0.000 description 60
- 201000010099 disease Diseases 0.000 description 53
- 125000003275 alpha amino acid group Chemical group 0.000 description 52
- 229910052500 inorganic mineral Inorganic materials 0.000 description 49
- 239000011707 mineral Substances 0.000 description 49
- 239000002773 nucleotide Substances 0.000 description 44
- 125000003729 nucleotide group Chemical group 0.000 description 44
- 208000002111 Eye Abnormalities Diseases 0.000 description 41
- 208000030533 eye disease Diseases 0.000 description 40
- 230000006399 behavior Effects 0.000 description 39
- 230000001771 impaired effect Effects 0.000 description 38
- 230000027288 circadian rhythm Effects 0.000 description 37
- 208000011580 syndromic disease Diseases 0.000 description 37
- 210000001519 tissue Anatomy 0.000 description 37
- 108010058846 Ovalbumin Proteins 0.000 description 35
- 230000005856 abnormality Effects 0.000 description 35
- 229940092253 ovalbumin Drugs 0.000 description 35
- 230000002207 retinal effect Effects 0.000 description 35
- 208000026278 immune system disease Diseases 0.000 description 34
- 230000002159 abnormal effect Effects 0.000 description 32
- 210000004970 cd4 cell Anatomy 0.000 description 28
- 230000002526 effect on cardiovascular system Effects 0.000 description 28
- 210000000952 spleen Anatomy 0.000 description 28
- 230000002491 angiogenic effect Effects 0.000 description 27
- 230000036506 anxiety Effects 0.000 description 27
- 230000003511 endothelial effect Effects 0.000 description 27
- 210000000265 leukocyte Anatomy 0.000 description 27
- 230000004973 motor coordination Effects 0.000 description 27
- 230000006371 metabolic abnormality Effects 0.000 description 26
- 230000001404 mediated effect Effects 0.000 description 25
- 208000001132 Osteoporosis Diseases 0.000 description 23
- 239000002158 endotoxin Substances 0.000 description 21
- 206010020718 hyperplasia Diseases 0.000 description 21
- 229920006008 lipopolysaccharide Polymers 0.000 description 21
- 230000006977 prepulse inhibition Effects 0.000 description 21
- 210000001550 testis Anatomy 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 19
- 208000014674 injury Diseases 0.000 description 19
- 208000013403 hyperactivity Diseases 0.000 description 18
- 230000002950 deficient Effects 0.000 description 17
- 208000024985 Alport syndrome Diseases 0.000 description 16
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 16
- 208000002177 Cataract Diseases 0.000 description 16
- 208000011688 Generalised anxiety disease Diseases 0.000 description 16
- 208000003807 Graves Disease Diseases 0.000 description 16
- 208000015023 Graves' disease Diseases 0.000 description 16
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 16
- 206010068871 Myotonic dystrophy Diseases 0.000 description 16
- 206010029113 Neovascularisation Diseases 0.000 description 16
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 16
- 208000004453 Retinal Dysplasia Diseases 0.000 description 16
- 201000007737 Retinal degeneration Diseases 0.000 description 16
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 16
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 16
- 206010047115 Vasculitis Diseases 0.000 description 16
- 230000005744 arteriovenous malformation Effects 0.000 description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 208000029364 generalized anxiety disease Diseases 0.000 description 16
- 201000011066 hemangioma Diseases 0.000 description 16
- 208000005252 hepatitis A Diseases 0.000 description 16
- 208000003215 hereditary nephritis Diseases 0.000 description 16
- 208000017169 kidney disease Diseases 0.000 description 16
- 150000002632 lipids Chemical class 0.000 description 16
- 230000004258 retinal degeneration Effects 0.000 description 16
- 206010039073 rheumatoid arthritis Diseases 0.000 description 16
- 206010019280 Heart failures Diseases 0.000 description 15
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 15
- 208000002865 osteopetrosis Diseases 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 238000002054 transplantation Methods 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 14
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- 210000000577 adipose tissue Anatomy 0.000 description 14
- 230000001054 cortical effect Effects 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- 210000004072 lung Anatomy 0.000 description 14
- 210000000440 neutrophil Anatomy 0.000 description 14
- 210000001986 peyer's patch Anatomy 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 230000024188 startle response Effects 0.000 description 14
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 14
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 208000002780 macular degeneration Diseases 0.000 description 13
- 208000020925 Bipolar disease Diseases 0.000 description 12
- 230000003920 cognitive function Effects 0.000 description 12
- 201000003723 learning disability Diseases 0.000 description 12
- 230000035488 systolic blood pressure Effects 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 10
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 10
- 208000004454 Hyperalgesia Diseases 0.000 description 10
- 208000035154 Hyperesthesia Diseases 0.000 description 10
- 208000020764 Sensation disease Diseases 0.000 description 10
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 10
- 230000001363 autoimmune Effects 0.000 description 10
- 208000010877 cognitive disease Diseases 0.000 description 10
- 230000007850 degeneration Effects 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 10
- 230000002757 inflammatory effect Effects 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 201000000980 schizophrenia Diseases 0.000 description 10
- 208000019116 sleep disease Diseases 0.000 description 10
- 208000020685 sleep-wake disease Diseases 0.000 description 10
- 201000001320 Atherosclerosis Diseases 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 210000003169 central nervous system Anatomy 0.000 description 9
- 208000010125 myocardial infarction Diseases 0.000 description 9
- 208000009304 Acute Kidney Injury Diseases 0.000 description 8
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 8
- 206010002329 Aneurysm Diseases 0.000 description 8
- 206010002383 Angina Pectoris Diseases 0.000 description 8
- 208000003120 Angiofibroma Diseases 0.000 description 8
- 201000003076 Angiosarcoma Diseases 0.000 description 8
- 200000000007 Arterial disease Diseases 0.000 description 8
- 206010051113 Arterial restenosis Diseases 0.000 description 8
- 206010003694 Atrophy Diseases 0.000 description 8
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 8
- 208000004597 Bacillary angiomatosis Diseases 0.000 description 8
- 201000001321 Bardet-Biedl syndrome Diseases 0.000 description 8
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 8
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 8
- 201000004569 Blindness Diseases 0.000 description 8
- 206010007559 Cardiac failure congestive Diseases 0.000 description 8
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 8
- 208000006029 Cardiomegaly Diseases 0.000 description 8
- 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 description 8
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 8
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 8
- 208000033810 Choroidal dystrophy Diseases 0.000 description 8
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 8
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 8
- 208000010200 Cockayne syndrome Diseases 0.000 description 8
- 208000015943 Coeliac disease Diseases 0.000 description 8
- 206010009900 Colitis ulcerative Diseases 0.000 description 8
- 208000011231 Crohn disease Diseases 0.000 description 8
- 206010011777 Cystinosis Diseases 0.000 description 8
- 208000016192 Demyelinating disease Diseases 0.000 description 8
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 8
- 201000010374 Down Syndrome Diseases 0.000 description 8
- 206010015218 Erythema multiforme Diseases 0.000 description 8
- 208000004332 Evans syndrome Diseases 0.000 description 8
- 208000024720 Fabry Disease Diseases 0.000 description 8
- 208000024412 Friedreich ataxia Diseases 0.000 description 8
- 208000027472 Galactosemias Diseases 0.000 description 8
- 208000010412 Glaucoma Diseases 0.000 description 8
- 206010018364 Glomerulonephritis Diseases 0.000 description 8
- 201000005618 Glomus Tumor Diseases 0.000 description 8
- 206010018498 Goitre Diseases 0.000 description 8
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 8
- 208000007698 Gyrate Atrophy Diseases 0.000 description 8
- 201000009492 Hallermann-Streiff syndrome Diseases 0.000 description 8
- 208000001258 Hemangiosarcoma Diseases 0.000 description 8
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 8
- 208000005176 Hepatitis C Diseases 0.000 description 8
- 208000005331 Hepatitis D Diseases 0.000 description 8
- 208000037319 Hepatitis infectious Diseases 0.000 description 8
- 206010020365 Homocystinuria Diseases 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 8
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 8
- 208000003456 Juvenile Arthritis Diseases 0.000 description 8
- 206010048804 Kearns-Sayre syndrome Diseases 0.000 description 8
- 206010056715 Laurence-Moon-Bardet-Biedl syndrome Diseases 0.000 description 8
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 8
- 206010025219 Lymphangioma Diseases 0.000 description 8
- 208000018501 Lymphatic disease Diseases 0.000 description 8
- 206010025282 Lymphoedema Diseases 0.000 description 8
- 208000027933 Mannosidase Deficiency disease Diseases 0.000 description 8
- 208000001826 Marfan syndrome Diseases 0.000 description 8
- 208000000743 Marshall syndrome Diseases 0.000 description 8
- 108700000227 Marshall syndrome Proteins 0.000 description 8
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 8
- 208000001089 Multiple system atrophy Diseases 0.000 description 8
- 201000002481 Myositis Diseases 0.000 description 8
- 208000035023 Oculocerebrorenal syndrome of Lowe Diseases 0.000 description 8
- 201000010183 Papilledema Diseases 0.000 description 8
- 206010033712 Papilloedema Diseases 0.000 description 8
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 8
- 208000018262 Peripheral vascular disease Diseases 0.000 description 8
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 8
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 8
- 208000034541 Rare lymphatic malformation Diseases 0.000 description 8
- 208000005587 Refsum Disease Diseases 0.000 description 8
- 208000033626 Renal failure acute Diseases 0.000 description 8
- 206010063837 Reperfusion injury Diseases 0.000 description 8
- 208000007135 Retinal Neovascularization Diseases 0.000 description 8
- 206010038923 Retinopathy Diseases 0.000 description 8
- 208000034517 Saldino-Mainzer syndrome Diseases 0.000 description 8
- 206010039710 Scleroderma Diseases 0.000 description 8
- 208000006045 Spondylarthropathies Diseases 0.000 description 8
- 208000027073 Stargardt disease Diseases 0.000 description 8
- 208000027077 Stickler syndrome Diseases 0.000 description 8
- 201000009594 Systemic Scleroderma Diseases 0.000 description 8
- 208000004732 Systemic Vasculitis Diseases 0.000 description 8
- 206010042953 Systemic sclerosis Diseases 0.000 description 8
- 206010043189 Telangiectasia Diseases 0.000 description 8
- 206010044688 Trisomy 21 Diseases 0.000 description 8
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 8
- 201000006704 Ulcerative Colitis Diseases 0.000 description 8
- 208000014769 Usher Syndromes Diseases 0.000 description 8
- 206010047112 Vasculitides Diseases 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 208000026724 Waardenburg syndrome Diseases 0.000 description 8
- 208000022482 Wagner disease Diseases 0.000 description 8
- 208000027207 Whipple disease Diseases 0.000 description 8
- 201000010802 Wolfram syndrome Diseases 0.000 description 8
- 206010052428 Wound Diseases 0.000 description 8
- 201000004525 Zellweger Syndrome Diseases 0.000 description 8
- 208000036813 Zellweger spectrum disease Diseases 0.000 description 8
- 208000004622 abetalipoproteinemia Diseases 0.000 description 8
- 201000011040 acute kidney failure Diseases 0.000 description 8
- 208000012998 acute renal failure Diseases 0.000 description 8
- 208000030597 adult Refsum disease Diseases 0.000 description 8
- 206010003246 arthritis Diseases 0.000 description 8
- 208000010927 atrophic thyroiditis Diseases 0.000 description 8
- 230000037444 atrophy Effects 0.000 description 8
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 8
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 8
- 208000019748 bullous skin disease Diseases 0.000 description 8
- 208000026106 cerebrovascular disease Diseases 0.000 description 8
- 208000003571 choroideremia Diseases 0.000 description 8
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 8
- 208000006623 congenital stationary night blindness Diseases 0.000 description 8
- 201000001981 dermatomyositis Diseases 0.000 description 8
- 201000011190 diabetic macular edema Diseases 0.000 description 8
- 208000010643 digestive system disease Diseases 0.000 description 8
- 201000007192 granulomatous hepatitis Diseases 0.000 description 8
- 208000002672 hepatitis B Diseases 0.000 description 8
- 201000010284 hepatitis E Diseases 0.000 description 8
- 230000001553 hepatotropic effect Effects 0.000 description 8
- 239000007943 implant Substances 0.000 description 8
- 201000006334 interstitial nephritis Diseases 0.000 description 8
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 8
- 230000000366 juvenile effect Effects 0.000 description 8
- 208000012804 lymphangiosarcoma Diseases 0.000 description 8
- 208000018555 lymphatic system disease Diseases 0.000 description 8
- 208000002502 lymphedema Diseases 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 206010027191 meningioma Diseases 0.000 description 8
- 201000006417 multiple sclerosis Diseases 0.000 description 8
- 201000003142 neovascular glaucoma Diseases 0.000 description 8
- 201000006352 oculocerebrorenal syndrome Diseases 0.000 description 8
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 description 8
- 208000001749 optic atrophy Diseases 0.000 description 8
- 208000014380 ornithine aminotransferase deficiency Diseases 0.000 description 8
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 8
- 210000001428 peripheral nervous system Anatomy 0.000 description 8
- 208000005987 polymyositis Diseases 0.000 description 8
- 208000037803 restenosis Diseases 0.000 description 8
- 210000001927 retinal artery Anatomy 0.000 description 8
- 230000004233 retinal vasculature Effects 0.000 description 8
- 201000007714 retinoschisis Diseases 0.000 description 8
- 201000000306 sarcoidosis Diseases 0.000 description 8
- 230000037390 scarring Effects 0.000 description 8
- 208000010157 sclerosing cholangitis Diseases 0.000 description 8
- 201000002464 short-rib thoracic dysplasia 9 with or without polydactyly Diseases 0.000 description 8
- 208000017520 skin disease Diseases 0.000 description 8
- 201000005671 spondyloarthropathy Diseases 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 8
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 8
- 208000009056 telangiectasis Diseases 0.000 description 8
- 206010043554 thrombocytopenia Diseases 0.000 description 8
- 201000005060 thrombophlebitis Diseases 0.000 description 8
- 206010043778 thyroiditis Diseases 0.000 description 8
- 230000008733 trauma Effects 0.000 description 8
- 230000002792 vascular Effects 0.000 description 8
- 201000011531 vascular cancer Diseases 0.000 description 8
- 206010055031 vascular neoplasm Diseases 0.000 description 8
- 208000037997 venous disease Diseases 0.000 description 8
- 206010000349 Acanthosis Diseases 0.000 description 7
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 7
- 108010082126 Alanine transaminase Proteins 0.000 description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
- 206010068783 Alstroem syndrome Diseases 0.000 description 7
- 201000005932 Alstrom Syndrome Diseases 0.000 description 7
- 201000004940 Bloch-Sulzberger syndrome Diseases 0.000 description 7
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 7
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 7
- 206010011017 Corneal graft rejection Diseases 0.000 description 7
- 206010055665 Corneal neovascularisation Diseases 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 206010011878 Deafness Diseases 0.000 description 7
- 206010011953 Decreased activity Diseases 0.000 description 7
- 201000004624 Dermatitis Diseases 0.000 description 7
- 206010012438 Dermatitis atopic Diseases 0.000 description 7
- 206010012442 Dermatitis contact Diseases 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 208000001860 Eye Infections Diseases 0.000 description 7
- 208000004520 Flynn-Aird syndrome Diseases 0.000 description 7
- 208000004262 Food Hypersensitivity Diseases 0.000 description 7
- 206010016946 Food allergy Diseases 0.000 description 7
- 208000009329 Graft vs Host Disease Diseases 0.000 description 7
- 206010053759 Growth retardation Diseases 0.000 description 7
- 208000002125 Hemangioendothelioma Diseases 0.000 description 7
- 208000006050 Hemangiopericytoma Diseases 0.000 description 7
- 206010019842 Hepatomegaly Diseases 0.000 description 7
- 206010020524 Hydronephrosis Diseases 0.000 description 7
- 206010020649 Hyperkeratosis Diseases 0.000 description 7
- 206010020843 Hyperthermia Diseases 0.000 description 7
- 206010064919 Hypospermia Diseases 0.000 description 7
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 7
- 208000007031 Incontinentia pigmenti Diseases 0.000 description 7
- 208000011327 Increased bone mineral density Diseases 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 208000007766 Kaposi sarcoma Diseases 0.000 description 7
- 208000007466 Male Infertility Diseases 0.000 description 7
- 201000009906 Meningitis Diseases 0.000 description 7
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 7
- 206010029379 Neutrophilia Diseases 0.000 description 7
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 201000004681 Psoriasis Diseases 0.000 description 7
- 206010039085 Rhinitis allergic Diseases 0.000 description 7
- 201000006760 Senior-Loken syndrome Diseases 0.000 description 7
- 108010071390 Serum Albumin Proteins 0.000 description 7
- 102000007562 Serum Albumin Human genes 0.000 description 7
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 7
- 206010052779 Transplant rejections Diseases 0.000 description 7
- 102100040247 Tumor necrosis factor Human genes 0.000 description 7
- 208000024780 Urticaria Diseases 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 206010000891 acute myocardial infarction Diseases 0.000 description 7
- 208000026935 allergic disease Diseases 0.000 description 7
- 201000010105 allergic rhinitis Diseases 0.000 description 7
- 208000006673 asthma Diseases 0.000 description 7
- 201000008937 atopic dermatitis Diseases 0.000 description 7
- 230000002146 bilateral effect Effects 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 7
- 208000010247 contact dermatitis Diseases 0.000 description 7
- 201000000159 corneal neovascularization Diseases 0.000 description 7
- 231100000895 deafness Toxicity 0.000 description 7
- 230000007547 defect Effects 0.000 description 7
- 206010061811 demyelinating polyneuropathy Diseases 0.000 description 7
- 210000004443 dendritic cell Anatomy 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 206010014599 encephalitis Diseases 0.000 description 7
- 201000009580 eosinophilic pneumonia Diseases 0.000 description 7
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 7
- 206010016165 failure to thrive Diseases 0.000 description 7
- 210000001280 germinal center Anatomy 0.000 description 7
- 208000024908 graft versus host disease Diseases 0.000 description 7
- 231100000001 growth retardation Toxicity 0.000 description 7
- 210000003128 head Anatomy 0.000 description 7
- 208000016354 hearing loss disease Diseases 0.000 description 7
- 208000003906 hydrocephalus Diseases 0.000 description 7
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 7
- 230000036031 hyperthermia Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 208000000509 infertility Diseases 0.000 description 7
- 230000036512 infertility Effects 0.000 description 7
- 231100000535 infertility Toxicity 0.000 description 7
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000006742 locomotor activity Effects 0.000 description 7
- 210000002751 lymph Anatomy 0.000 description 7
- 206010025226 lymphangitis Diseases 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 230000000527 lymphocytic effect Effects 0.000 description 7
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 7
- 150000002826 nitrites Chemical class 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 210000000496 pancreas Anatomy 0.000 description 7
- 210000003200 peritoneal cavity Anatomy 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 229910052698 phosphorus Inorganic materials 0.000 description 7
- 239000011574 phosphorus Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 201000009732 pulmonary eosinophilia Diseases 0.000 description 7
- 230000000384 rearing effect Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 210000003079 salivary gland Anatomy 0.000 description 7
- 210000001732 sebaceous gland Anatomy 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 230000007958 sleep Effects 0.000 description 7
- 230000021595 spermatogenesis Effects 0.000 description 7
- 230000035882 stress Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000004489 tear production Effects 0.000 description 7
- 230000005747 tumor angiogenesis Effects 0.000 description 7
- 230000002485 urinary effect Effects 0.000 description 7
- 208000008811 Agoraphobia Diseases 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- 206010002859 Anxiety disorder due to a general medical condition Diseases 0.000 description 6
- 101100137548 Arabidopsis thaliana PRF4 gene Proteins 0.000 description 6
- 206010003805 Autism Diseases 0.000 description 6
- 208000020706 Autistic disease Diseases 0.000 description 6
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- 208000020401 Depressive disease Diseases 0.000 description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 6
- 208000020358 Learning disease Diseases 0.000 description 6
- 208000019022 Mood disease Diseases 0.000 description 6
- 101150066369 PRO3 gene Proteins 0.000 description 6
- 206010033664 Panic attack Diseases 0.000 description 6
- 206010052794 Panic disorder with agoraphobia Diseases 0.000 description 6
- 206010033668 Panic disorder without agoraphobia Diseases 0.000 description 6
- 206010034912 Phobia Diseases 0.000 description 6
- 208000021386 Sjogren Syndrome Diseases 0.000 description 6
- 206010041250 Social phobia Diseases 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 6
- 208000011962 Substance-induced mood disease Diseases 0.000 description 6
- 231100000395 Substance-induced mood disorder Toxicity 0.000 description 6
- 208000033017 acquired idiopathic inflammatory myopathy Diseases 0.000 description 6
- 208000029650 alcohol withdrawal Diseases 0.000 description 6
- 208000030963 borderline personality disease Diseases 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 206010008129 cerebral palsy Diseases 0.000 description 6
- 208000026725 cyclothymic disease Diseases 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- 206010015037 epilepsy Diseases 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 208000024714 major depressive disease Diseases 0.000 description 6
- 210000000822 natural killer cell Anatomy 0.000 description 6
- 208000019906 panic disease Diseases 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 208000022821 personality disease Diseases 0.000 description 6
- 208000028173 post-traumatic stress disease Diseases 0.000 description 6
- 201000001716 specific phobia Diseases 0.000 description 6
- 230000008736 traumatic injury Effects 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 208000029725 Metabolic bone disease Diseases 0.000 description 5
- 208000025966 Neurological disease Diseases 0.000 description 5
- 206010049088 Osteopenia Diseases 0.000 description 5
- 206010064930 age-related macular degeneration Diseases 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 102100022361 CAAX prenyl protease 1 homolog Human genes 0.000 description 4
- 101000677540 Homo sapiens Acetyl-CoA carboxylase 2 Proteins 0.000 description 4
- 101000824531 Homo sapiens CAAX prenyl protease 1 homolog Proteins 0.000 description 4
- 101001003584 Homo sapiens Prelamin-A/C Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 102100021334 Bcl-2-related protein A1 Human genes 0.000 description 3
- 101000894929 Homo sapiens Bcl-2-related protein A1 Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000035871 PIK3CA-related overgrowth syndrome Diseases 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000003145 cytotoxic factor Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- 101150115324 ACC2 gene Proteins 0.000 description 1
- 101100137546 Arabidopsis thaliana PRF2 gene Proteins 0.000 description 1
- 208000031638 Body Weight Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 101150004094 PRO2 gene Proteins 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 102400000745 Potential peptide Human genes 0.000 description 1
- 101800001357 Potential peptide Proteins 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 101000942305 Zea mays Cytokinin dehydrogenase 1 Proteins 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000002787 antisense oligonuctleotide Substances 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000004047 hyperresponsiveness Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/14—Organic oxygen compounds
- A21D2/145—Acids, anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D10/00—Batters, dough or mixtures before baking
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/14—Organic oxygen compounds
- A21D2/16—Fatty acid esters
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/14—Organic oxygen compounds
- A21D2/18—Carbohydrates
- A21D2/183—Natural gums
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/14—Organic oxygen compounds
- A21D2/18—Carbohydrates
- A21D2/185—Biosynthetic gums
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/14—Organic oxygen compounds
- A21D2/18—Carbohydrates
- A21D2/186—Starches; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/14—Organic oxygen compounds
- A21D2/18—Carbohydrates
- A21D2/188—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/10—Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/269—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
- A23L29/27—Xanthan not combined with other microbial gums
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05394030 | 2005-11-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200804180B true ZA200804180B (en) | 2009-08-26 |
Family
ID=36000846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200804180A ZA200804180B (en) | 2005-11-07 | 2008-05-14 | Bread improver comprising emulsifier and stabiliser |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20080233240A1 (fr) |
| EP (1) | EP1947951A1 (fr) |
| JP (1) | JP2009514514A (fr) |
| AU (1) | AU2006310708A1 (fr) |
| BR (1) | BRPI0618286A2 (fr) |
| CA (1) | CA2628651A1 (fr) |
| MA (1) | MA29974B1 (fr) |
| MX (1) | MX2008005945A (fr) |
| TN (1) | TNSN08200A1 (fr) |
| WO (1) | WO2007051647A1 (fr) |
| ZA (1) | ZA200804180B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1982597A1 (fr) * | 2007-04-20 | 2008-10-22 | Puratos N.V. | Produit de remplacement des matières grasses pour des applications de boulangerie et de pâtisserie |
| US8137578B2 (en) * | 2007-06-18 | 2012-03-20 | Cargill, Incorporated | Leaching resistant pre-wetted deicer composition |
| WO2011063473A1 (fr) * | 2009-11-27 | 2011-06-03 | Serrol Ingredients Pty Limited | Composition d'émulsifiant |
| BE1024782B1 (nl) * | 2016-07-11 | 2018-07-02 | Puratos Nv | Verbeterde samenstelling voor bakkerijproducten |
| CN106262765A (zh) * | 2016-09-28 | 2017-01-04 | 广州嘉德乐生化科技有限公司 | 一种马铃薯粉的复合乳化剂及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4539215A (en) * | 1983-07-07 | 1985-09-03 | General Foods Corporation | Emulsification system for creamy food products |
| US5215774A (en) * | 1987-10-20 | 1993-06-01 | The Pillsbury Company | Self-topping cake |
| US4940595A (en) * | 1987-10-27 | 1990-07-10 | The Pillsbury Company | Controlling the texture of microwave brownies |
| EP0468552A3 (en) * | 1990-06-06 | 1993-12-22 | Merck & Co Inc | Shortening substitute for bakery products |
| AUPM922194A0 (en) * | 1994-11-03 | 1994-11-24 | Burns Philp Food Holdings Pty Limited | Liquid bread improver |
| AU2003226459A1 (en) * | 2003-03-31 | 2004-10-25 | Council Of Scientific And Industrial Research | Improver premix for chapatis comprising ascorbic acid, sodium stearoyl lactylate and guar gum |
| US20040213883A1 (en) * | 2003-04-24 | 2004-10-28 | Sadek Nagwa Zaki | Dough that browns, raises and forms an oven tender bread crust under the influence of microwave incident energy |
| GB0312606D0 (en) * | 2003-06-02 | 2003-07-09 | Cereform Ltd | Aqueous stabilization of liquid dough conditioning compositions |
-
2006
- 2006-11-07 CA CA002628651A patent/CA2628651A1/fr not_active Abandoned
- 2006-11-07 AU AU2006310708A patent/AU2006310708A1/en not_active Abandoned
- 2006-11-07 WO PCT/EP2006/010634 patent/WO2007051647A1/fr active Application Filing
- 2006-11-07 EP EP06818393A patent/EP1947951A1/fr not_active Withdrawn
- 2006-11-07 JP JP2008538309A patent/JP2009514514A/ja active Pending
- 2006-11-07 BR BRPI0618286-0A patent/BRPI0618286A2/pt not_active Application Discontinuation
- 2006-11-07 MX MX2008005945A patent/MX2008005945A/es not_active Application Discontinuation
- 2006-11-07 US US12/092,839 patent/US20080233240A1/en not_active Abandoned
-
2008
- 2008-05-06 TN TNP2008000200A patent/TNSN08200A1/en unknown
- 2008-05-14 ZA ZA200804180A patent/ZA200804180B/en unknown
- 2008-05-26 MA MA30964A patent/MA29974B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1947951A1 (fr) | 2008-07-30 |
| BRPI0618286A2 (pt) | 2011-08-23 |
| AU2006310708A1 (en) | 2007-05-10 |
| CA2628651A1 (fr) | 2007-05-10 |
| US20080233240A1 (en) | 2008-09-25 |
| JP2009514514A (ja) | 2009-04-09 |
| MX2008005945A (es) | 2008-10-17 |
| TNSN08200A1 (en) | 2009-10-30 |
| WO2007051647A1 (fr) | 2007-05-10 |
| MA29974B1 (fr) | 2008-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7947866B2 (en) | Gene disruptions, compositions and methods relating thereto | |
| US7858843B2 (en) | Gene disruptions, compositions and methods relating thereto | |
| US20120005766A1 (en) | Methods of identifying agents that modulate phenotypes related to disruptions, of a gene encoding PRO235 polypeptide | |
| US20110182883A1 (en) | Novel gene disruptions, compositions and methods relating thereto | |
| US20090288176A1 (en) | Novel Gene Disruptions, Compositions and Methods Relating Thereto | |
| US20110252485A1 (en) | Novel gene disruptions, compositions and methods relating thereto | |
| ZA200804180B (en) | Bread improver comprising emulsifier and stabiliser | |
| US20110200579A1 (en) | Novel gene disruptions, compositions and methods relating thereto | |
| US20100233153A1 (en) | Novel gene disruptions, compositions and the methods relating thereto |